ATLASXeris Biopharma (XERS) earnings date: Nov 5, 2026
Xeris Biopharma (XERS) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 5, 2026, before the open. Analysts expect EPS of $0.02.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on XERS
| Last price | $10.21 (-4.7%) |
|---|---|
| Normal 1-day range (±1σ) | ±3.3% |
| Earnings beat history | Beat the EPS estimate in 2 of the last 6 reports |
These figures come from the same calibrated model and valuation as the Xeris Biopharma stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Xeris Biopharma reports on Nov 5, 2026. One email the day before, with ATLAS’s read on Xeris Biopharma. You can switch it off at any time.
Alert me before XERS reportsFree to start. Creating an account takes under a minute.
Notify me when Xeris Biopharma reports
Track XERS free Add Xeris Biopharma to a free ATLAS watchlist and see its next report date in one place.
XERS earnings at a glance
| Next report (confirmed) | Thu, Nov 5, 2026 |
|---|---|
| Time | Before the open |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | $0.02 |
| Last report | Aug 6, 2026 · Miss |
| Beat rate (last 6 reports) | 2 of 6 (33%) |
| Average EPS surprise | +10.9% |
| Average move around a report | ±2.4% (last 6) |
| Sector | Healthcare · Biotechnology |
Xeris Biopharma earnings history: last 6 reports
Xeris Biopharma last reported on Aug 6, 2026: EPS of -$0.01 against an estimate of $0.02 (-150.0% surprise), a miss.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 6, 2026 | $0.02 | -$0.01 | -150.0% | Miss | -2.2% |
| May 7, 2026 | -$0.01 | $0.01 | +200.0% | Beat | +2.5% |
| Mar 2, 2026 | $0.05 | $0.06 | +20.0% | Beat | -2.9% |
| Feb 20, 2026 | $1.57 | $1.50 | -4.5% | Miss | -2.2% |
| Jan 28, 2026 | $1.03 | $1.03 | 0.0% | In line | -3.6% |
| Oct 8, 2025 | $0.04 | $0.04 | 0.0% | In line | -1.1% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for XERS
See the fair value, the probability range and the earnings history of Xeris Biopharma on its ATLAS page.
Xeris Biopharma (XERS) stock analysisPlans from €3.99 a month.
Xeris Biopharma earnings: frequently asked questions
When does Xeris Biopharma (XERS) report earnings?
Xeris Biopharma is scheduled to report on Thursday, November 5, 2026, before the open. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for XERS?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is $0.02 per share (USD). Estimates can change before the report.
How often does XERS beat earnings estimates?
Of its last 6 reports with a recorded result, Xeris Biopharma beat the EPS estimate 2 times; the average surprise was +10.9%. Past results do not predict the next one.
How much does XERS move around earnings?
Over its last 6 reports the stock moved an average of 2.4% (absolute, from the close before the report day to the close after it), and finished higher 1 of 6 times.
Did Xeris Biopharma beat earnings estimates last quarter?
Xeris Biopharma last reported on Aug 6, 2026: EPS of -$0.01 against an estimate of $0.02 (-150.0% surprise), a miss.
How much does XERS usually move in a day?
On a normal trading day the ATLAS model puts XERS’s one-day range at about ±3.3%, with a 50% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 5, 2026
Educational information, not investment advice. Disclaimer